Agamree® (vamorolone) – New orphan drug approval
October 26, 2023 - Catalyst Pharmaceuticals announced the FDA approval of Agamree (vamorolone), for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Download PDF
